Close Menu

NEW YORK (GenomeWeb) – Becton Dickinson announced today that it has received approval from the US Food and Drug Administration for its BD Max Vaginal Panel for the diagnosis of vaginitis and vaginosis in women who exhibit symptoms of vaginal infections. 

The assay runs on the BD Max System, which combines automated real-time PCR extraction, amplification, and detection on a single platform. It is designed to detect the pathogens responsible for bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.